|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Melanoma differentiation associated gene-7 (mda-7) selectively promotes these effects in cancer cells. mda-7 was identified more than two decades ago by subtraction hybridization showing elevated expression during induction of terminal differentiation of metastatic melanoma cells following treatment with recombinant fibroblast interferon and mezerein (a PKC activating agent).
|
31356866 |
2019 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to elucidate whether antitumor effects could be augmented by the combination of TMZ and IFN‑β in malignant melanoma.
|
30864696 |
2019 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results illustrate that engineered hNSCs prevented malignant melanoma cells from proliferating in the presence of the prodrug, and the form that secreted IFN-β intervened in the EMT process and melanoma metastasis.
|
30213181 |
2019 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The precise mechanisms underlying the tumor-suppressive effects of IFN-β on melanoma are not yet completely understood.
|
31070806 |
2019 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adjuvant therapy with low-dose interferon-beta for stage II and III melanoma: results of a retrospective analysis.
|
28649738 |
2017 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we evaluated the cytotoxic effects of the combination of BTZ and IFNβ gene lipofection on cultured melanoma cell lines.
|
27677689 |
2017 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Intratumoral injection of IFN-β induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb.
|
28624449 |
2017 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The methylation level of the 5' IRF6 CGI was completely inversely correlated with cell sensitivity to interferon-β in eight examined melanoma cell lines.
|
28877249 |
2017 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON).
|
29136453 |
2017 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The combination of bleomycin with suicide or interferon-β gene transfer is able to efficiently eliminate human melanoma tumor initiating cells.
|
27399807 |
2016 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CXCL10 reduced melanoma cell proliferation in IFN-β-sensitive cells as well as resistant cells.
|
26102027 |
2015 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the cytotoxic effects of interferon-β (IFNβ) gene lipofection on tumor cell lines derived from three human cutaneous and four canine mucosal melanomas.
|
26054674 |
2015 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, we identify an IFNβ1-dependent, cell-autonomous mechanism that contributes to the therapeutic resistance of melanoma via the PKCɛ-ATF2 regulatory axis.
|
25728676 |
2015 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
RA, co-administered with the dsRNA mimicker polyinosinic-polycytidylic acid (poly(I:C)), synergizes to mount a specific response program able to sense dsRNA through the concurrent upregulation of TLR3, the dsRNA helicases melanoma differentiation-associated antigen-5 (MDA-5) and RA-inducible gene-1 (RIG-1), and the dsRNA-activated protein kinase (PKR) expression, leading breast cancer cells to specifically express downstream transcriptional targets of dsRNA sensors, such as interferon-β (IFNβ), interleukin-8 (IL-8), chemokine (C-C motif) ligand 5 (CCL5), and C-X-C motif Chemokine 10 (CXCL10).
|
23370279 |
2013 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Difference of interferon-α and interferon-β on melanoma growth and lymph node metastasis in mice.
|
23358428 |
2013 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of IFNα and IFNβ in B16 cells efficiently suppressed the establishment of inoculated melanoma.
|
23018621 |
2012 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As hIFNβ gene was effective even in the rhIFNβ protein-resistant M8 cell line and in a way not limited by low lipofection efficiency, these results strongly support the clinical potential of this approach.
|
22555508 |
2012 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Subcutaneous C32 tumors in mice were sonicated weekly immediately after intra-tumor injection with IFN-β genes mixed with microbubbles.
|
21723255 |
2011 |
|
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Anti-tumor effects of canine adipose tissue-derived mesenchymal stromal cell-based interferon-β gene therapy and cisplatin in a mouse melanoma model.
|
21846298 |
2011 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sensitization of melanoma cells to temozolomide by IFN-β and VPA was also shown in a xenograft mouse model.
|
21493591 |
2011 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that HuIFNbeta gene therapy is an attractive strategy for the treatment of melanoma.
|
18945721 |
2008 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Up-regulation of human PNPase mRNA by beta-interferon has no effect on protein level in melanoma cell lines.
|
16505900 |
2006 |
|
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Intralesional therapy of metastatic spreading melanoma with beta-interferon.
|
16928243 |
2006 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Exogenously added human interferon-beta (HuIFN-beta) protein possesses a remarkable antiproliferative activity in human glioma and melanoma.
|
16343929 |
2005 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Interferon-beta from melanoma cells suppresses the proliferations of melanoma cells in an autocrine manner.
|
12096926 |
2002 |